Recombinant Human Proteinase-activated receptor 2 (F2RL1)

What is F2RL1 and how does it function at the molecular level?

F2RL1 (F2R Like Trypsin Receptor 1), also known as Proteinase-Activated Receptor 2 (PAR2), is a member of the G-protein coupled receptor 1 family. It functions through a unique activation mechanism involving proteolytic cleavage of its extracellular N-terminus, which reveals a new amino terminus that acts as a tethered ligand binding to an extracellular loop domain. This activation process initiates downstream signaling cascades through G-protein coupling. F2RL1 can be activated by various serine proteases, including pancreatic trypsin, thrombin, and tissue factor, triggering diverse biological responses related to inflammation, tumor development, and vascular function .

What are the key structural domains of F2RL1 that determine its functionality?

The F2RL1 receptor contains several critical structural domains that dictate its function. The extracellular N-terminal domain contains the proteolytic cleavage site that determines receptor activation. The transmembrane domains form the core of the receptor and participate in conformational changes following activation. Intracellular loops and the C-terminal domain interact with G-proteins and other signaling molecules to facilitate downstream signal transduction. The extracellular loop domains, particularly the second extracellular loop, contain the binding site for the tethered ligand exposed after proteolytic cleavage, which is crucial for receptor activation .

How does the activation mechanism of F2RL1 differ from conventional ligand-receptor interactions?

Unlike conventional ligand-receptor interactions where independent molecules bind to and activate receptors reversibly, F2RL1 activation involves an irreversible proteolytic cleavage of its N-terminal domain. This cleavage reveals a tethered ligand that remains attached to the receptor and binds to the extracellular loop, triggering activation. This mechanism creates a self-sustaining activation that cannot be readily terminated through ligand dissociation, resulting in prolonged signaling. This unique mechanism also means that once cleaved, the receptor cannot be reactivated by the same mechanism and must be replaced through new protein synthesis or receptor recycling .

What cell-based assay systems are most effective for studying F2RL1 signaling and pharmacology?

The Tango F2RL1-bla U2OS cell-based assay represents one of the most effective systems for studying F2RL1 signaling and pharmacology. This assay utilizes engineered U2OS cells containing human F2RL1 linked to a TEV protease site and a fluorescent substrate with two fluorophores (coumarin and fluorescein). Upon receptor activation, beta-arrestin recruitment leads to protease cleavage and subsequent reporter activation, resulting in a measurable fluorescent signal shift from green to blue. This technology has been validated in high-throughput screening campaigns and provides a normalized reporter response that minimizes experimental noise .

For comprehensive F2RL1 research, additional effective assay systems include calcium mobilization assays, ERK phosphorylation assays, and β-arrestin recruitment assays using BRET or FRET technologies. Each system offers specific advantages depending on the signaling pathway being investigated .

How should researchers optimize culture conditions when working with F2RL1-expressing cell lines?

When working with F2RL1-expressing cell lines, researchers should maintain cells in a humidified 37°C/5% CO2 incubator using appropriate assay medium. The Tango F2RL1-bla U2OS cells, for example, require careful handling with specific considerations. Researchers should avoid touching the bottom of assay plates, handle plates by the sides, and briefly centrifuge plates after adding reagents to ensure components are at the well bottoms. Cell density optimization is crucial, with recommended seeding at 10,000-12,000 cells per well in 384-well format. For stimulation experiments, a 16-hour incubation period is typically optimal. Researchers should also assess solvent effects (particularly DMSO, which should be kept below 0.5%) on assay performance before conducting screening campaigns .

What are the validated methods for quantifying F2RL1 expression levels in tissue samples?

Several validated methods exist for quantifying F2RL1 expression in tissue samples. RNA-sequencing (RNA-seq) provides comprehensive transcriptomic data and has been extensively used in cancer research databases like TCGA. Quantitative PCR (qPCR) offers a targeted approach for measuring F2RL1 mRNA expression with high sensitivity. For protein-level detection, immunohistochemistry (IHC) enables visualization of F2RL1 expression patterns within tissue architecture, while ELISA allows quantitative measurement of F2RL1 protein levels in serum or tissue lysates. Western blotting provides information on protein size and potential post-translational modifications .

In clinical research, standardized protocols for measuring F2RL1 in cervical scrapings have been developed, with samples collected in specialized containers for subsequent analysis using ELISA with commercially available Human F2RL1 Assay Kits. This approach has proven valuable for differentiating between normal and cancerous tissues .

How does F2RL1 expression correlate with cervical cancer progression and patient outcomes?

F2RL1 expression shows significant correlation with cervical cancer (CCa) progression and patient outcomes. Bioinformatic analysis of TCGA data reveals that F2RL1 is significantly upregulated in CCa tissues compared to normal tissues. Higher F2RL1 expression levels correlate with advanced pathological stages and poorer prognosis. The expression varies significantly between different pathological stages and cancer subtypes, with notable differences between squamous and adenocarcinoma subtypes .

Immunohistochemical validation confirms these findings, showing progressive increases in F2RL1 expression from normal tissue through various stages of cervical intraepithelial neoplasia (CIN-I, CIN-II, CIN-III) to invasive carcinoma. This progressive expression pattern suggests F2RL1 could serve as a valuable biomarker for early diagnosis and prognosis in CCa patients. Multivariate COX regression analyses further indicate that F2RL1 expression is an independent prognostic factor for CCa patient outcomes .

What mechanisms link F2RL1 activation to cancer cell migration and invasion?

F2RL1 activation promotes cancer cell migration and invasion through several interconnected mechanisms. Upon activation, F2RL1 initiates signaling cascades that modulate the tumor microenvironment by regulating the expression of pro-inflammatory cytokines and chemokines. This creates a favorable environment for tumor growth and metastasis. F2RL1 activation also enhances epithelial-to-mesenchymal transition (EMT), a critical process in cancer cell invasion, by altering cell adhesion molecules and cytoskeletal reorganization .

Additionally, F2RL1 signaling promotes angiogenesis by upregulating vascular endothelial growth factors and other angiogenic mediators, facilitating tumor vascularization and providing routes for metastasis. In cervical cancer, F2RL1 expression correlates with the depth of tumor invasion into the gastric wall, lymphatic and venous infiltration, and liver metastasis. Functional enrichment analysis reveals F2RL1's involvement in processes such as cilium movement, microtubule bundle formation, and axoneme assembly, all of which contribute to cellular motility and invasive capacity .

How does F2RL1 interact with the immune microenvironment in cancer progression?

F2RL1 plays a significant role in modulating the immune microenvironment during cancer progression. Bioinformatic analysis has identified 43 immune-related genes that show significant co-expression patterns with F2RL1 in cervical cancer. Protein-protein interaction network analysis further confirms F2RL1's central role in immune-related pathways. F2RL1 expression correlates with immune cell infiltration profiles, potentially influencing the recruitment and function of specific immune cell populations within the tumor microenvironment .

Single-sample Gene Set Enrichment Analysis (ssGSEA) demonstrates that F2RL1 expression levels correlate with markers for 24 different immune cell types. Spearman correlation analysis reveals significant associations between F2RL1 expression and immune checkpoint molecules like PDCD1 (PD-1) and CD274 (PD-L1), suggesting a potential role in immune evasion mechanisms. The Wilcoxon rank-sum test confirms differential immune cell infiltration between high and low F2RL1-expressing tumors, indicating that F2RL1 may influence immune surveillance and response in the tumor microenvironment .

What are the primary downstream signaling pathways activated by F2RL1 stimulation?

F2RL1 activation triggers multiple downstream signaling pathways that mediate its diverse biological effects. Upon stimulation, F2RL1 primarily couples to Gαq/11 proteins, leading to phospholipase C activation, inositol trisphosphate (IP3) generation, and subsequent calcium mobilization from intracellular stores. This calcium signaling is crucial for many cellular responses. F2RL1 also activates the mitogen-activated protein kinase (MAPK) pathway, particularly ERK1/2, promoting cell proliferation and survival .

Additionally, F2RL1 signaling activates the β-arrestin pathway, which not only contributes to receptor desensitization but also initiates G-protein-independent signaling. Functional enrichment analysis reveals F2RL1's involvement in multiple molecular functions, including anion transmembrane transporter activity, chloride transmembrane transporter activity, and solute:sodium symporter activity. KEGG pathway analysis shows that F2RL1 and its co-expressed genes are enriched in pathways such as neuroactive ligand-receptor interaction, bile secretion, and maturity onset diabetes of the young .

How do different proteases differentially activate F2RL1 and lead to biased signaling outcomes?

Different proteases can cleave the F2RL1 N-terminal domain at various sites, exposing distinct tethered ligands that may preferentially activate specific downstream signaling pathways—a phenomenon known as biased signaling. Proteases such as trypsin, tryptase, and factor Xa cleave at canonical activation sites (typically after arginine residues), leading to robust receptor activation across multiple pathways. Other proteases like neutrophil elastase may cleave at non-canonical sites, generating different tethered ligands that preferentially activate certain pathways over others .

This protease-specific activation contributes to the diverse and sometimes contradictory roles of F2RL1 in different physiological and pathological contexts. For instance, in cancer, different proteases in the tumor microenvironment may activate F2RL1 to promote either pro-tumorigenic or anti-tumorigenic effects depending on the specific downstream pathways activated. Understanding these differential activation mechanisms is critical for developing pathway-specific therapeutic strategies targeting F2RL1 .

What protein-protein interaction networks involve F2RL1 in inflammatory and oncogenic contexts?

F2RL1 participates in complex protein-protein interaction networks that differ between inflammatory and oncogenic contexts. In inflammatory settings, F2RL1 interacts with proteases released during tissue injury and inflammation, such as mast cell tryptase, neutrophil proteases, and coagulation factors. These interactions lead to receptor activation and subsequent pro-inflammatory signaling through cytokine and chemokine production .

In oncogenic contexts, bioinformatic analysis has revealed significant protein-protein interaction networks involving F2RL1 and 43 immune-related genes in cervical cancer. Using the CytoHubba plugin, researchers have identified the top ten important nodes in this network, highlighting critical interaction partners that may influence F2RL1's role in cancer progression. Co-expression analysis further demonstrates positive and negative correlations between F2RL1 and various genes, including the top 15 differentially expressed mRNAs associated with F2RL1 expression in cancer. These interaction networks provide insight into how F2RL1 may influence tumor growth, immune evasion, and metastasis through coordinated interactions with multiple molecular partners .

What methodological considerations are important when measuring F2RL1 activation in complex biological samples?

When measuring F2RL1 activation in complex biological samples, several methodological considerations are crucial. Sample preparation must preserve native protease activity while preventing non-specific receptor activation. For tissue samples, rapid flash-freezing and careful homogenization in protease-inhibitor-containing buffers are recommended to maintain receptor integrity. When using reporter-based assays like the Tango F2RL1-bla U2OS system, researchers must account for potential interference from endogenous proteases and fluorescent compounds in biological samples .

For clinical samples, standardized collection protocols are essential, as demonstrated in cervical cancer research where specialized containers are used for cervical scrapings to ensure sample integrity. ELISA-based detection methods require validation of antibody specificity, especially since F2RL1 shares structural similarities with other protease-activated receptors. Background normalization is particularly important in fluorescence-based assays, and the inclusion of appropriate controls (unstimulated, stimulated, and cell-free) is recommended to account for assay variability .

What strategies can overcome the challenges of generating specific antibodies against F2RL1?

Generating specific antibodies against F2RL1 presents significant challenges due to its structural similarity to other protease-activated receptors and its seven-transmembrane domain architecture. Several strategies can overcome these challenges. Researchers should target unique extracellular or intracellular regions of F2RL1 that share minimal homology with other PARs, particularly within the N-terminal region or intracellular C-terminus. Using synthetic peptides corresponding to these unique regions as immunogens can enhance specificity .

Extensive cross-reactivity testing against other PARs, particularly PAR1, is essential to validate antibody specificity. Complementary validation approaches, including using knockout/knockdown cells or tissues, competitive binding assays, and multiple antibodies targeting different epitopes, provide robust confirmation of specificity. For monoclonal antibody development, phage display technology and hybridoma screening with rigorous selection criteria can improve specificity. Additionally, using recombinant protein fragments rather than peptides as immunogens may preserve conformational epitopes and enhance antibody recognition of the native receptor .

How can researchers effectively control for endogenous protease activity in F2RL1 functional assays?

Controlling endogenous protease activity in F2RL1 functional assays requires a multi-faceted approach. Researchers should include protease inhibitor cocktails in assay buffers to minimize unwanted receptor activation, with careful selection of inhibitors that don't interfere with the specific proteases under investigation. Serum-free or defined media compositions help reduce variability from serum-derived proteases, while heat inactivation of serum components can further minimize unwanted protease activity .

The use of paired control experiments with protease-resistant F2RL1 mutants (where the cleavage site is mutated) provides an excellent internal control to distinguish specific activation from background activity. Enzyme-dead protease controls are also valuable for determining whether observed effects are due to proteolytic activity or non-catalytic protein interactions. Time-course experiments help distinguish between acute receptor activation and prolonged signaling, which is particularly important given F2RL1's irreversible activation mechanism. Additionally, specific F2RL1 antagonists can be employed to confirm that observed effects are receptor-mediated rather than off-target protease activities .

What are the current approaches for developing F2RL1 antagonists and their relative efficacies?

Current approaches for developing F2RL1 antagonists include small molecule inhibitors, peptidomimetics, and biologics, each with distinct efficacy profiles. Small molecule antagonists target the binding site of the tethered ligand or allosteric sites, preventing receptor activation. These compounds typically show moderate potency (IC50 values in the micromolar range) but often lack selectivity between PAR subtypes. Peptidomimetics designed to mimic the structure of the tethered ligand while blocking activation have demonstrated improved selectivity but may suffer from poor oral bioavailability and metabolic stability .

Biologics, including monoclonal antibodies targeting the F2RL1 extracellular domain, show high specificity and potency. These antibodies can block the interaction between the tethered ligand and its binding site or prevent proteolytic cleavage altogether. Recent advances in aptamer technology have also yielded promising F2RL1 antagonists with nanomolar affinities. Antisense oligonucleotides and siRNA approaches targeting F2RL1 expression represent alternative strategies that have shown efficacy in preclinical models, particularly in cancer contexts where F2RL1 overexpression contributes to disease progression .

How might targeting F2RL1 impact cancer immunotherapy strategies?

Targeting F2RL1 could significantly impact cancer immunotherapy strategies based on its established role in modulating the tumor immune microenvironment. F2RL1 expression correlates with immune cell infiltration profiles and immune checkpoint molecules like PD-1 and PD-L1, suggesting potential synergistic effects when combining F2RL1 inhibitors with immune checkpoint blockade therapies. By modulating the inflammatory tumor microenvironment, F2RL1 antagonists might enhance T-cell infiltration and activation within tumors, potentially overcoming resistance mechanisms to existing immunotherapies .

Bioinformatic analyses have identified 43 immune-related genes with significant co-expression patterns with F2RL1 in cervical cancer, indicating that F2RL1 targeting could reset the immune landscape within tumors. F2RL1 inhibition might reduce the recruitment of immunosuppressive cell populations while promoting anti-tumor immune responses. Additionally, since F2RL1 activation influences angiogenesis, combined targeting of F2RL1 and vascular pathways could enhance drug delivery to tumors while reducing hypoxia-induced immunosuppression. These multifaceted effects position F2RL1 as a promising target for combination immunotherapy strategies, particularly in cancers where it is overexpressed, such as cervical cancer .

What biomarkers could predict response to F2RL1-targeted therapies in cancer patients?

Several potential biomarkers could predict response to F2RL1-targeted therapies in cancer patients. F2RL1 expression levels in tumor tissue, as assessed by immunohistochemistry or RT-PCR, represent the most direct biomarker, with higher expression potentially indicating greater sensitivity to F2RL1 antagonists. Serum levels of F2RL1, measurable by ELISA, might serve as a less invasive biomarker, as shown in cervical cancer studies where F2RL1 serum levels correlate with disease progression .

Protease expression profiles in the tumor microenvironment could indicate the degree of endogenous F2RL1 activation and therefore potential responsiveness to F2RL1 inhibition. Genetic analysis of the 43 immune-related genes that show significant co-expression with F2RL1 might provide a signature that predicts therapy response. Additionally, immune cell infiltration patterns, particularly the ratio of effector to suppressor immune cells, could serve as predictive biomarkers given F2RL1's role in immune modulation. Combinations of these biomarkers, potentially analyzed through machine learning approaches, might yield higher predictive value than any single marker, enabling more precise patient selection for F2RL1-targeted therapies .

How might single-cell analysis technologies advance our understanding of F2RL1 biology?

Single-cell analysis technologies represent a transformative approach for understanding F2RL1 biology by revealing cell-type-specific expression patterns and signaling heterogeneity previously masked in bulk tissue analyses. Single-cell RNA sequencing (scRNA-seq) can identify specific cell populations expressing F2RL1 within complex tissues, particularly valuable in tumor microenvironments where multiple cell types interact. This approach could reveal unexpected F2RL1-expressing cells and novel cellular interactions mediated by F2RL1 signaling .

Single-cell proteomics techniques, including mass cytometry (CyTOF) and imaging mass cytometry, can simultaneously track F2RL1 expression alongside multiple signaling molecules, revealing how F2RL1 activation affects different pathways in individual cells. Spatial transcriptomics and advanced imaging techniques like multiplexed ion beam imaging (MIBI) could map F2RL1 expression within tissue architecture, providing insight into how F2RL1-expressing cells interact with their microenvironment. These technologies could uncover cell-specific roles of F2RL1 in disease progression and identify new therapeutic opportunities targeting specific cellular compartments where F2RL1 signaling is most relevant .

What novel experimental models could better recapitulate F2RL1 signaling in human disease?

Novel experimental models that better recapitulate F2RL1 signaling in human disease include advanced three-dimensional organoid cultures derived from patient tissues, which maintain tissue architecture and cellular heterogeneity while allowing for controlled experimental manipulation. These organoids can be developed from various tissues where F2RL1 plays important roles, including cervical, colorectal, and pancreatic tissues, providing disease-specific models for studying F2RL1 function .

Patient-derived xenograft (PDX) models preserve tumor heterogeneity and microenvironment components, allowing for in vivo assessment of F2RL1 targeting in a context that closely resembles human disease. Humanized mouse models with reconstituted human immune systems are particularly valuable for studying F2RL1's role in modulating immune responses in cancer and inflammatory conditions. Microfluidic organ-on-a-chip systems can model complex tissue interactions, such as tumor-stroma-immune cell interactions, while maintaining precise control over experimental conditions. CRISPR-engineered cell and animal models with specific F2RL1 mutations can recapitulate patient-specific variants, enabling personalized disease modeling. These advanced models will provide more translatable insights into F2RL1's role in human disease than traditional cell culture systems .

How might computational approaches advance F2RL1-targeted drug discovery?

Computational approaches offer powerful tools to accelerate F2RL1-targeted drug discovery through multiple avenues. Molecular docking and virtual screening of compound libraries against F2RL1 structural models can identify novel antagonists with improved selectivity profiles. Machine learning algorithms trained on existing F2RL1 modulators can predict new chemical scaffolds with desired properties, expanding the chemical space of potential therapeutic compounds .

Network pharmacology approaches analyzing the 43 immune-related genes and protein interaction networks associated with F2RL1 could identify indirect targeting strategies or combination approaches that modulate F2RL1 signaling networks rather than the receptor itself. Molecular dynamics simulations can reveal conformational changes in F2RL1 upon activation by different proteases, potentially identifying allosteric binding sites for more selective targeting. Systems biology modeling of F2RL1 signaling pathways could predict the consequences of pathway perturbations and help prioritize specific nodes for therapeutic intervention .

Additionally, bioinformatic analysis of patient datasets, as demonstrated in cervical cancer research, can identify biomarkers for patient stratification and predict therapeutic responses to F2RL1-targeted agents, enabling more personalized treatment approaches. These computational strategies, when integrated with experimental validation, promise to significantly accelerate the development of effective F2RL1-targeting therapeutics for cancer and inflammatory diseases .